Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 9/20 | 0.60 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | CTSG | P08311 | 1/20 | 0.42 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4969646 | 0.76 | POLB (0.61) | POLBMEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL16362032 | 0.76 | NISCH (0.52) | P2RX4POLBELANECTSGPRTN3 | |
| SCHEMBL8630231 | 0.72 | P2RX4 (0.48) | P2RX4ALDH1A1 | |
| SCHEMBL8632712 | 0.72 | P2RX4 (0.48) | P2RX4ALDH1A1 | |
| SCHEMBL4970309 | 0.71 | ALDH1A1 (0.48) | POLBELANECTSGPRTN3MEN1 | |
| SCHEMBL4409521 | 0.70 | P2RX4 (0.49) | P2RX4BCHEALDH1A1 | |
| SCHEMBL19527738 | 0.70 | REN (0.44) | POLBELANECTSGPRTN3MEN1 | |
| SCHEMBL17027045 | 0.69 | ALPL (0.49) | POLBELANECTSGPRTN3MEN1 | |
| SCHEMBL20752138 | 0.69 | SLC9A1 (0.52) | P2RX4ELANECTSGPRTN3ALDH1A1 | |
| SCHEMBL28965671 | 0.69 | P2RX4 (0.44) | P2RX4BCHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | P2RX4 414/4885BCHE 1364/4885POLB 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.